WHO WE ARE
A New Approach
Sanaregen Vision Therapeutics is a biotechnology company founded by an award- winning advocate and a healthspan neuroscientist dedicated to creating affordable and accessible vision-restoring therapies. Using strategies that blend innovative approaches with regenerative medicine and other cell-based technologies, Sanaregen Vision Therapeutics applies over 100 years of combined experience in neuroscience, regulatory affairs, patient advocacy, and retinal research, to align each product toward unmet needs of those suffering debilitating vision loss.
Our Approach
Every drug therapy project we undertake employs a core commitment to create better, more effective cell-based therapies. To help accomplish this, we work closely with partners who share our goals of improving vision, not just slowing down disease.
Our Vision
Our vision is to be a leading provider of innovative medical solutions and technologies that improve patient outcomes and advance the field of medicine, especially conditions that are rare, or where current therapies offer limited hope.
Regenerative Therapy for Blinding Retinal Diseases
Sanaregen Vision Therapeutics has a clear focus: developing regenerative therapies that have the best chance of helping patients reclaim their lives. To that end, our 2024-2027 vision pipeline targets drusen-related retinal diseases, including Familial Drusen and advanced Geographic Atrophy.